Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET

Company Participants

Will O’Connor – Stern Investor Relations
Mike Andriole – President and Chief Executive Officer
Allen Melemed – Chief Medical Officer
Josh Allen – Chief Technology Officer
Michelle LaSpaluto – Chief Financial Officer
Tom Riga – Chief Operating and Commercial Officer

Conference Call Participants

Maury Raycroft – Jefferies
Naureen Quibria – Capital One
Soumit Roy – Jones Research
Troy Langford – TD Cowen

Operator

Good morning, ladies and gentlemen, and welcome to the Chimerix First Quarter 2024 Earnings Conference Call.

I would now like to introduce you to your host for today’s call, Will O’Connor of Stern Investor Relations. Please proceed.

Will O’Connor

Thank you, operator. Good morning, everyone, and welcome to the Chimerix first quarter 2024 financial and operating results conference call. This morning, we issued a press release related to our first quarter operating update. You can access the press release in our Investors section of the website.

With me on today’s call are President and Chief Executive Officer, Mike Andriole; Chief Medical Officer, Allen Melemed; Chief Operating and Commercial Officer, Tom Riga; Chief Financial Officer, Michelle LaSpaluto; and Chief Technology Officer, Josh Allen.

Before we begin, I’d like to remind you that the statements made on today’s call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors.

These risks and uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Please refer to our filings with the SEC for a more complete disclosure of these risks and uncertainties.

At this time, I’ll now turn the call over to Chimerix President and Chief Executive Officer, Mike Andriole.

Mike Andriole

Thanks, Will, and good morning, everyone, and thank you for joining us. I’m pleased to be joined this morning by other members of our senior leadership team to share an update on a productive quarter across several key initiatives. Of primary strategic importance to Chimerix this year is the continued focus and drive of enrollment in the Phase 3 ACTION study, for which the team continued to execute at a high level during the first quarter.

The study remains on track, the first interim readout next year and is reaching steady state accrual. The success of the ACTION study, which is the most advanced trial in H3 K27M-mutant glioma is central to our strategy as a positive outcome likely represents approval of the first medicine to treat this specific disease.